|  |  |  |  |
| --- | --- | --- | --- |
| **Criteria Title** | Lipopeptide Antibacterials | | |
| **Criteria Subtitle** | Cubicin (daptomycin) | | |
| **Approval Level** | GCNSeqNo | | |
| **Products**   |  |  | | --- | --- | | Preferred |  | | Non-Preferred |  | | Brand |  | | Generic |  | | Other |  | | Drug Name | Corresponding Code(s) | Type of Code (GCNSeqNo, HICL, NDC) |
| CUBICIN | 053190 | GCNSeqNo |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Sequence Number** | **Question ID** | **Default Next Question ID** | **Question Type** | **Question Text** | **Choice Text** | **Next Question ID** |
| 1 | 1000 |  | Select | Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling? | Y | 1001 |
| N | 1235 |
| 2 | 1001 |  | Select and Free Text | Is the request for a continuation of Cubicin (daptomycin) treatment that was initiated in the hospital?  If yes, please submit documentation. | Y | END (Approve x 42 days) |
| N | 1235 |
| 3 | 1235 |  | Free Text | Please provide the rationale for the medication being requested. | END (Pending Manual Review) | |

LENGTH OF AUTHORIZATIONS: Up to 42 days

|  |  |
| --- | --- |
| **Last Approved** | 4/11/2023 |
| **Other** |  |